Fresh from the iwCLL, CLL expert Dr. William Plunkett, Professor in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center shares the latest news on CLL therapeutics with Andrew. Dr. Plunkett is on the cutting edge of biological therapy and speaks confidently of the progression of CLL treatments. Listen as he states, The future is bright for development ofdemonstrably curative CLL therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Author: admin
Can patient care be coordinated regardless of what country you live in? When should an MPN patient start seeking expert care? MPN expert Dr. Bart Scott, Director of Hematology and Hematologic Malignancies at Seattle Cancer Care Alliance, answers these questions. Dr. Scott also discusses when an MPN patient may require changes to their treatment and what those options are, including clinical trials. Listen as Dr. Scott explains why this is a hopeful time for MPN patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ |…
At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Toni Choueiri, MD of the Dana-Farber Cancer Institute welcomes viewers to the 14th International Kidney Cancer Symposium 2015
Toni Choueiri, MD of the Dana-Farber Cancer Institute How Does the Axitinib Plus Pembrolizumab study impact future research?
Toni Choueiri, MD of the Dana-Farber Cancer Institute discusses the Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses the next steps Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer what are the next steps?
Michael Bassetti MD PhD of University of Wisconsin Madison discusses What’s the Impact to Physicians Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer an Overview
Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP. For more information, visit http://www.cancertypeid.com
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the impact of the Oncotype DX® Breast Cancer Assay, a multigene assay that stratifies patients into risk groups that are associated with distant recurrence and response to adjuvant chemotherapy, on treatment decisions for patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa, a prospective, global observational study that was designed to describe patterns of care and outcomes for men with late-stage prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology-organised multidisciplinary Task Force, which focuses on reviewing access to innovation in all fields of oncology. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of baseline genetic heterogeneities on progression-free survival in patients with advanced BRAF V600-mutated melanoma treated with cobimetinib plus vemurafenib in the phase 3 coBRIM clinical trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, randomised, phase 3 clinical trial that was designed to evaluate bevacizumab combined with chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel or topotecan) for patients with platinum-resistant recurrent ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the understanding of BRAF-mutant melanoma biology, which involves the constitutive activation of the MAPK pathway, that have led to the development of new targeted therapies for patients with metastatic disease. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in breast cancer. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, reviews the predictive and prognostic value of currently available multigene assays for the management of patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
The Oncotype DX® Breast Cancer Assay, a multigene assay, stratifies breast cancer patients into groups that are at low, intermediate or high risk for distant recurrence and guides decision making for adjuvant chemotherapy. At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, explains the factors that were associated with the implementation of the Oncotype DX assay in different healthcare systems. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single-arm clinical trial of atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, as first-line or subsequent therapy for patients with locally advanced or metastatic PD-L1-selected non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) phase 2 BELIEF clinical trial, which evaluated erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without the T790M mutation. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety data from the phase 1b part of MASTERKEY-265 , a phase 1b/3 clinical trial that was designed to evaluate the treatment of talimogene laherparepvec (T-VEC), a herpes simplex virus-1, and pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with unresectable stage IIIB-IV melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
@OncEd Presents Dr. Enriqueta Felip – Targeted therapies in ALK-positive NSCLC
@OncEd Presents Dr. Simon Raphael – Actionable biomarkers in NSCLC: EGFR and ALK
@OncEd Presents Dr. Keith Flaherty – Integrating new treatment options for melanoma
@OncEd Presents Dr. Keith Flaherty – An expert’s perspective on frequently asked questions on BRAF V600-mutated advanced melanoma
@OncEd Presents – Dr. Natasha Leighl & Dr. David Hogg – Immune Response Vs. RECIST Criteria
@OncEd Presents Dr. Lori Wood – Optimizing Outcomes in Advanced Prostate Cancer
Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by NHS on a daily basis, to improve the outcomes of cancer patients.
Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference covers the whole range of cancer research from prevention and early diagnosis through basic science, translational science, clinical research, survivorship and palliative care research. Karen Kennedy also discusses recent NCRI initiatives on pathology research, and long-standing initiatives on radiotherapy and survivorship.
Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he explains what is epigenetics, it’s role in cancer cells and the importance of developing novel cancer treatments that inhibit the regulation of this mechanism.
Robert Coleman, MBBS, MD, FRCP, a trustee of Breast Cancer Now, discusses the goals of the newly formed charity that resulted from the combination of Breakthrough Breast Cancer and Breast Cancer Campaign. The charity has set the goal to prevent breast cancer death by 2050, which will be achieved by continuing to provide funding to breast cancer treatment, but also focusing on prevention, policies and economics in breast cancer.
Kevin Brindle, PhD gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he described a new technique called nuclear spin hyperpolarization, that can increase the sensitivity of the magnetic resonance by 10,000 fold. This technique can have several uses, including detection of treatment response and investigation of tumour microenvironment. In his talk Kevin Brindle focuses on the use of this technique in brain tumours.
Harpal Kumar, MA MEng MBA DSc gives an overview of his session at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he discusses the efforts of the National Awareness and Early Diagnosis Initiative (NAEDI) to develop a better understanding of the contribution of late diagnosis to the UK’s relatively poor cancer survival rates and develop strategies to address this.
Miriam Johnson, MD gives an overview of a session at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, that focuses on the importance of providing GPs and oncologists with a tool that can help them systematically assess the patient and carer needs. These needs can range from physical and psychological symptoms to legal, financial and work related matters that could directly affect the quality of life and cancer patients and their carers. The session hosted talk by Irene Higginson, Wei Gao and Christina Remsenthaler.
With the advent of unlocking genetic code, the cancer community has now been introduced to the concept of immunotherapy. What does this mean specifically for MPN patients? For MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center, genetics hold many answers but add a level of complexity related to prognosis and treatment. Dr. Mark Heaney of Columbia University Cancer Center views genetics in terms of interpreting how aggressive the disease may be, while Bob Rosen, patient advocate and Chairman of MPN Research Foundation, suggests that patients put the role of genetics into perspective by connecting with a specialist. Get…
In this segment of The Conversation, MPN Edition, Dr. Srdan Verstovsek of MD Anderson Cancer Center, MPN expert Dr. Mark Heaney of Columbia University Cancer Center, and Bob Rosen, Chair of MPN Research Foundation share their insight and views on clinical trial participation. Listen closely as the guests discuss the differences between the REVEAL study and the PEGASYS trial, highlighting the outcomes, reasons, and options for both participation and non-participation in clinical trials and observational studies. As Bob Rosen says, it’s a “balancing act for patients and their doctors to decide.” Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube |…
CLL patients with certain genetic markers are considered to be high risk and their options for treatment have historically been limited. CLL expert Dr. Jeff Sharman joins Patient Power to discuss emerging approaches to treating high-risk CLL currently being studied in clinical trials. Sponsored through an educational grant from TG Therapeutics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
MPN experts Dr. Mark Heaney of Columbia University Cancer Center and Dr. Srdan Verstovek of MD Anderson Cancer Center examine the expanding polycythemia vera (PV) armamentarium, answering the question, “Where are we now?” Dr. Heaney discusses second generation inhibitors and customization of treatment, while Dr. Verstovek focuses on combination therapies and expanded options coming from interferon trials in Europe. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Michael Keating, a leading researcher from MD Anderson Cancer Center, has had a career that spans decades and has witnessed the evolution of CLL research. Andrew Schorr, the founder of Patient Power, sat down with Dr. Keating to discuss promising developments in CLL research and Dr. Keatings ongoing commitment: to stay alive until CLL is cured. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Paolo Boffetta, MD, MPH gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. In his talk he discusses how the burden of cancer can be reduced by dietary modifications. Prof. Boffetta also highlights the importance of having a healthy and balanced diet, which includes fruit, vegetables and protein, and to try and avoid focusing on one specific food item or chemical element.
Rebecca Fitzgerald, MD, FAAD gives an overview of a session presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, focusing on molecular testing for early cancer diagnosis. The session included talks by Marc Tischkowitz and Peter Sasieni. Marc Tischkowitz focused on tests for genetic predisposition of ovarian cancer and results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study, whilst Peter Sasieni addressed the bigger question about biomarkers and how they are useful at different stages of early detection. Rebecca Fitzgerald also introduces Cytosponge, a non-endoscopic cell collection tool that in combination with oesophageal biomarkers can aid…
Chad Creighton of the Baylor College of Medicine: “How does the Papillary RCC: The Cancer Genome Atlas (TCGA) impact Physicians?”
Chad Creighton of Baylor College of Medicine discusses the next steps for Papillary RCC: The Cancer Genome Atlas (TCGA)
Chad Creighton of Baylor College of Medicine discusses a short overview of the Papillary RCC: The Cancer Genome Atlas (TCGA)
Tim Hunt, FRS, FMedSci describes the path that led him to identify cyclin-dependent kinases (CDK), along with colleagues Paul Nurse and Leland Hartwell, that would eventually lead to the award of a Nobel Prize in Physiology or Medicine in 2001.